|
J&J said in a statement it was "pleased" with the panel's vote and will continue working with the agency to bring its drug to market. The company is studying canagliflozin in nine studies enrolling more than 10,000 patients. It notes this is the largest research effort of its kind submitted to FDA for a diabetes drug. If the FDA approves the New Brunswick, N.J., company's drug, it would be the first in a new class medicines called SGLT2 inhibitors. The agency rejected another experimental drug in the SGLT2 class, dapagliflozin from partners Bristol-Myers Squibb Co. and AstraZeneca PLC, a year ago. The FDA cited concerns about possible liver damage and elevated rates of bladder and breast cancer. The FDA has set a target date of March 31 to decide whether to approve U.S. sales of canagliflozin. Johnson and Johnson would sell it under the brand name Invokana.
Copyright 2013 The Associated
Press. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Community |
Perspectives
|
Law & Courts |
Leisure Time
|
Spiritual Life |
Health & Fitness |
Teen Scene
Calendar
|
Letters to the Editor